TY - JOUR
T1 - Impact of gender on long-term mortality in patients with unprotected left main disease
T2 - The Milan and New-Tokyo (MITO) Registry
AU - Takagi, Kensuke
AU - Chieffo, Alaide
AU - Shannon, Joanne
AU - Naganuma, Toru
AU - Tahara, Satoko
AU - Fujino, Yusuke
AU - Latib, Azeem
AU - Montorfano, Matteo
AU - Carlino, Mauro
AU - Kawamoto, Hiroyoshi
AU - Nakamura, Sunao
AU - Colombo, Antonio
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Background Although percutaneous intervention (PCI) for ULM is common, the impact of gender remains unclear. This study aimed to clarify the impact of gender in patients treated with drug-eluting stents (DES) for unprotected left main (ULM) disease. Methods Between April 2002 and August 2011, 1026 consecutive patients (212 women and 814 men) undergoing PCI using first or second generation DES for ULM stenosis were analyzed. Study endpoints included major adverse cardiac events (MACE) defined as composite of all-cause death, myocardial infarction (MI), and target lesion revascularization (TLR). Individual components of MACE and cardiac death were also evaluated. Results Women had greater comorbidity and more complex lesions, resulting in a higher incidence of cardiac death, TLR and MI {[HR, 1.94 (95% CI, 1.22–3.09, p = 0.005)], [HR, 1.31 (95% CI 0.96–1.81), p = 0.09] and [HR, 2.04 (95% CI, 0.98–4.25), p = 0.06], respectively}. Propensity score matching identified 131 matched pairs. There were no differences in MACE [HR, 1.04 (95% CI, 0.68–1.61, p = 0.85)], all-cause death [HR, 0.96 (95% CI, 0.52–1.77), p = 0.89] or MI [HR, 0.84 (95% CI, 0.21–3.50, p = 0.84)]. However, cardiac death [HR, 2.70 (95% CI, 0.98–7.49, p = 0.056] and TLR [HR, 1.62 (95% CI, 0.93–2.84), p = 0.09] showed a trend to being higher in women compared to men. Conclusions In patients with ULM disease, women had greater comorbidity and more complex lesions, resulting in an increased risk of clinical events. However after propensity matching, there was no difference in the occurrence of MACE but cardiac death showed a trend to being higher in women compared to men.
AB - Background Although percutaneous intervention (PCI) for ULM is common, the impact of gender remains unclear. This study aimed to clarify the impact of gender in patients treated with drug-eluting stents (DES) for unprotected left main (ULM) disease. Methods Between April 2002 and August 2011, 1026 consecutive patients (212 women and 814 men) undergoing PCI using first or second generation DES for ULM stenosis were analyzed. Study endpoints included major adverse cardiac events (MACE) defined as composite of all-cause death, myocardial infarction (MI), and target lesion revascularization (TLR). Individual components of MACE and cardiac death were also evaluated. Results Women had greater comorbidity and more complex lesions, resulting in a higher incidence of cardiac death, TLR and MI {[HR, 1.94 (95% CI, 1.22–3.09, p = 0.005)], [HR, 1.31 (95% CI 0.96–1.81), p = 0.09] and [HR, 2.04 (95% CI, 0.98–4.25), p = 0.06], respectively}. Propensity score matching identified 131 matched pairs. There were no differences in MACE [HR, 1.04 (95% CI, 0.68–1.61, p = 0.85)], all-cause death [HR, 0.96 (95% CI, 0.52–1.77), p = 0.89] or MI [HR, 0.84 (95% CI, 0.21–3.50, p = 0.84)]. However, cardiac death [HR, 2.70 (95% CI, 0.98–7.49, p = 0.056] and TLR [HR, 1.62 (95% CI, 0.93–2.84), p = 0.09] showed a trend to being higher in women compared to men. Conclusions In patients with ULM disease, women had greater comorbidity and more complex lesions, resulting in an increased risk of clinical events. However after propensity matching, there was no difference in the occurrence of MACE but cardiac death showed a trend to being higher in women compared to men.
KW - Drug-eluting stent
KW - Gender difference
KW - Unprotected left main coronary artery
UR - http://www.scopus.com/inward/record.url?scp=84989955532&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84989955532&partnerID=8YFLogxK
U2 - 10.1016/j.carrev.2016.05.007
DO - 10.1016/j.carrev.2016.05.007
M3 - Article
C2 - 27460302
AN - SCOPUS:84989955532
SN - 1553-8389
VL - 17
SP - 369
EP - 374
JO - Cardiovascular Revascularization Medicine
JF - Cardiovascular Revascularization Medicine
IS - 6
ER -